Literature DB >> 30488259

A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.

Bruno Ramos-Molina1,2, Daniel Castellano-Castillo1,2, Oscar Pastor3, Luis Ocaña-Wilhelmi4, Diego Fernández-García5, Manuel Romero-Gómez6, Fernando Cardona7,8, Francisco J Tinahones1,2.   

Abstract

BACKGROUND: Non-alcoholic steatohepatitis (NASH) is present in a high percentage of obese patients undergoing bariatric surgery. A significant proportion of patients still present NASH even after considerable weight loss and metabolic improvements after surgery.
OBJECTIVE: To determine whether the changes in the serum lipidome after sleeve gastrectomy could be used to discriminate obese patients with NASH patients to those with non-alcoholic fatty liver (NAFL).
METHODS: This study involved 24 patients with grade 3 obesity diagnosed with either NAFL (n = 8) or NASH (n = 16) using the non-invasive OWLiver assay. All patients suffering from NASH were re-evaluated 6 months after bariatric surgery using the OWLiver test to confirm NASH resolution. Serum lipid extracts were assessed at baseline and 6 months post surgery and were analyzed in an ultra-performance liquid chromatography/time-of-flight mass spectrometry (UPLC-TOF-MS)-based platform.
RESULTS: Lipidomic analysis revealed a differential sphingomyelin profile in patients with NASH resolution after sleeve gastrectomy. Certain serum sphingomyelin species were significantly higher at baseline in NASH patients in comparison to those with NAFL. Sphingomyelin profile of subjects with NASH resolution was similar to that for obese subjects with NAFL before bariatric surgery.
CONCLUSION: Our study indicates that the serum sphingomyelin levels could be related to the status of non-alcoholic fatty liver disease and that certain sphingomyelin species may be used for the follow-up of obese patients with NASH after sleeve gastrectomy.

Entities:  

Keywords:  Bariatric surgery; Lipidomics; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Sleeve gastrectomy; Sphingolipids; Sphingomyelins

Mesh:

Substances:

Year:  2019        PMID: 30488259     DOI: 10.1007/s11695-018-3612-2

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  32 in total

1.  Role of ceramides in nonalcoholic fatty liver disease.

Authors:  Mangesh Pagadala; Takhar Kasumov; Arthur J McCullough; Nizar N Zein; John P Kirwan
Journal:  Trends Endocrinol Metab       Date:  2012-05-17       Impact factor: 12.015

Review 2.  Sphingolipids and glycerophospholipids - The "ying and yang" of lipotoxicity in metabolic diseases.

Authors:  S Rodriguez-Cuenca; V Pellegrinelli; M Campbell; M Oresic; A Vidal-Puig
Journal:  Prog Lipid Res       Date:  2017-01-16       Impact factor: 16.195

Review 3.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

4.  Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.

Authors:  Aayed Alqahtani; Mohamed Elahmedi; Khalid Alswat; Maha Arafah; Mosa Fagih; Jaehoon Lee
Journal:  Surg Obes Relat Dis       Date:  2017-04-07       Impact factor: 4.734

5.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.

Authors:  Guillaume Lassailly; Robert Caiazzo; David Buob; Marie Pigeyre; Hélène Verkindt; Julien Labreuche; Violeta Raverdy; Emmanuelle Leteurtre; Sébastien Dharancy; Alexandre Louvet; Monique Romon; Alain Duhamel; François Pattou; Philippe Mathurin
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

6.  The plasma lipidomic signature of nonalcoholic steatohepatitis.

Authors:  Puneet Puri; Michelle M Wiest; Onpan Cheung; Faridoddin Mirshahi; Carol Sargeant; Hae-Ki Min; Melissa J Contos; Richard K Sterling; Michael Fuchs; Huiping Zhou; Steven M Watkins; Arun J Sanyal
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

7.  Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum.

Authors:  Anna Kotronen; Tuulikki Seppänen-Laakso; Jukka Westerbacka; Tuula Kiviluoto; Johanna Arola; Anna-Liisa Ruskeepää; Hannele Yki-Järvinen; Matej Oresic
Journal:  Obesity (Silver Spring)       Date:  2009-10-01       Impact factor: 5.002

Review 8.  The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.

Authors:  Pedro Paulo Caravatto; Ricardo Cohen
Journal:  Curr Atheroscler Rep       Date:  2017-10-07       Impact factor: 5.113

9.  Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Piotr Kalinowski; Rafał Paluszkiewicz; Bogna Ziarkiewicz-Wróblewska; Tadeusz Wróblewski; Piotr Remiszewski; Mariusz Grodzicki; Marek Krawczyk
Journal:  Ann Surg       Date:  2017-11       Impact factor: 12.969

10.  Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis.

Authors:  Kosuke Saito; Takashi Uebanso; Keiko Maekawa; Masaki Ishikawa; Ryo Taguchi; Takao Nammo; Tomoko Nishimaki-Mogami; Haruhide Udagawa; Masato Fujii; Yuichiro Shibazaki; Hiroyuki Yoneyama; Kazuki Yasuda; Yoshiro Saito
Journal:  Sci Rep       Date:  2015-08-20       Impact factor: 4.379

View more
  3 in total

Review 1.  Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.

Authors:  Mojgan Masoodi; Amalia Gastaldelli; Tuulia Hyötyläinen; Enara Arretxe; Cristina Alonso; Melania Gaggini; Julia Brosnan; Quentin M Anstee; Oscar Millet; Pablo Ortiz; Jose M Mato; Jean-Francois Dufour; Matej Orešič
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-10       Impact factor: 46.802

2.  Common Transcriptional Program of Liver Fibrosis in Mouse Genetic Models and Humans.

Authors:  Kaja Blagotinšek Cokan; Žiga Urlep; Miha Moškon; Miha Mraz; Xiang Yi Kong; Winnie Eskild; Damjana Rozman; Peter Juvan; Tadeja Režen
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

3.  The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction.

Authors:  Ben Jones; Caroline Sands; Kleopatra Alexiadou; James Minnion; George Tharakan; Preeshila Behary; Ahmed R Ahmed; Sanjay Purkayastha; Matthew R Lewis; Stephen Bloom; Jia V Li; Tricia M Tan
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.